Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 10/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668525 | 0.89 | HTR2B (0.47) | HTR2BDGAT1NAMPT | |
| SCHEMBL3806049 | 0.85 | TDP1 (0.51) | NAMPT | |
| SCHEMBL3634211 | 0.83 | SLC18A3 (0.49) | HTR2BDGAT1NAMPTSLC18A3BACE1 | |
| SCHEMBL3720982 | 0.78 | HTR2B (0.50) | HTR2BDGAT1NAMPTSMYD3BACE1 | |
| SCHEMBL3303482 | 0.78 | DGAT1 (0.48) | HTR2BDGAT1NAMPTSMYD3SLC18A3 | |
| SCHEMBL3810068 | 0.77 | SLC18A3 (0.54) | HTR2BDGAT1NAMPTSLC18A3 | |
| SCHEMBL3304712 | 0.77 | HPGD (0.55) | HTR2BSLC18A3 | |
| SCHEMBL3637906 | 0.74 | ROCK2 (0.41) | DGAT1NAMPTSLC18A3BACE1 | |
| SCHEMBL3297763 | 0.74 | HTT (0.53) | HTR2BNAMPT | |
| SCHEMBL520567 | 0.74 | NAMPT (0.55) | NAMPTSMYD3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | HTR2B 3311/4885DGAT1 2/4885NAMPT 291/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | HTR2B 3311/4885DGAT1 2/4885NAMPT 291/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | HTR2B 3311/4885DGAT1 2/4885NAMPT 291/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | HTR2B 3311/4885DGAT1 2/4885NAMPT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.